semaglutide vs tirzepatide

semaglutide (S-tier) vs tirzepatide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

semaglutide · tier S

A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.

Strong obesity, cardiovascular, kidney, and MASH evidence, but each result belongs to its own product, route, population, and label.

14.9% STEP 1 mean weight change · half-life ~1 week · weight loss

tirzepatide · tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

20.9% SURMOUNT-1 mean change at 15 mg · half-life ~5 days · weight loss

at a glance

• semaglutide: tier S · 14.9% STEP 1 mean weight change
• tirzepatide: tier S · 20.9% SURMOUNT-1 mean change at 15 mg

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.